CAROL WAMBOLDT: Open Payments
NPI 1316975048 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,531 in 84 payments from 16 companies in 2025. Trend: 2023 $856 · 2024 $1,267 · 2025 $1,531
Food & beverage: $1,531
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $664 |
| Eisai Inc. | 4 | $134 |
| Lundbeck LLC | 5 | $129 |
| EMD Serono, Inc. | 4 | $91 |
| Teva Pharmaceuticals USA, Inc. | 3 | $86 |
| Neurelis, Inc. | 4 | $84 |
| Alnylam Pharmaceuticals Inc. | 2 | $61 |
| TG Therapeutics, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
Products named: QULIPTA, Leqembi, BOTOX, VYEPTI, UBRELVY, AJOVY, VALTOCO, AMVUTTRA.
Industry payments across MD — which companies pay providers there.
